TransCode Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪4.52 M‬USD
−782.8560USD
‪−17.56 M‬USD
‪6.54 M‬
Beta (1Y)
1.10

About TransCode Therapeutics, Inc.

CEO
Thomas A. Fitzgerald
Headquarters
Boston
Employees (FY)
19
Founded
2016
ISIN
US89357L3033
FIGI
BBG00ZGYHV03
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Forex, Futures, Bonds
4.5Great

See all brokers